Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Prognostic Value of Serum and Ascites Levels of Estradiol, FSH, LH and Prolactin in Ovarian Cancer

FRANK CHIH-KANG CHEN, GUELTEN OSKAY-ÖZCELIK, KAI J. BÜHLING, UTA KÖPSTEIN, MONIKA MENTZE, WERNER LICHTENEGGER and JALID SEHOULI
Anticancer Research May 2009, 29 (5) 1575-1578;
FRANK CHIH-KANG CHEN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: frank.chen{at}charite.de
GUELTEN OSKAY-ÖZCELIK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAI J. BÜHLING
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
UTA KÖPSTEIN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MONIKA MENTZE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
WERNER LICHTENEGGER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JALID SEHOULI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 29 no. 5 1575-1578
PMID 
19443368

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received October 6, 2008
  • Revision received December 17, 2008
  • Accepted January 26, 2009
  • Published online May 13, 2009.

Copyright & Usage 
Copyright© 2009 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

Author Information

  1. FRANK CHIH-KANG CHEN,
  2. GUELTEN OSKAY-ÖZCELIK,
  3. KAI J. BÜHLING,
  4. UTA KÖPSTEIN,
  5. MONIKA MENTZE,
  6. WERNER LICHTENEGGER and
  7. JALID SEHOULI
  1. Department of Gynecology and Obstetrics, Charité University Medicine Berlin, Campus Virchow-Klinikum, Germany
  1. Correspondence to: Dr. med. Frank Chih-Kang Chen, Department of Gynecology and Obstetrics Charité University Medicine Berlin Campus Virchow-Klinikum Augustenburger Platz 1 13353 Berlin, Germany. Tel: +4930450664069, Fax: +4930450564901, e-mail: frank.chen{at}charite.de
View Full Text

Statistics from Altmetric.com

Cited By...

  • 18 Citations
  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 29, Issue 5
May 2009
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
  • Back Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Prognostic Value of Serum and Ascites Levels of Estradiol, FSH, LH and Prolactin in Ovarian Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
9 + 9 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Prognostic Value of Serum and Ascites Levels of Estradiol, FSH, LH and Prolactin in Ovarian Cancer
FRANK CHIH-KANG CHEN, GUELTEN OSKAY-ÖZCELIK, KAI J. BÜHLING, UTA KÖPSTEIN, MONIKA MENTZE, WERNER LICHTENEGGER, JALID SEHOULI
Anticancer Research May 2009, 29 (5) 1575-1578;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Prognostic Value of Serum and Ascites Levels of Estradiol, FSH, LH and Prolactin in Ovarian Cancer
FRANK CHIH-KANG CHEN, GUELTEN OSKAY-ÖZCELIK, KAI J. BÜHLING, UTA KÖPSTEIN, MONIKA MENTZE, WERNER LICHTENEGGER, JALID SEHOULI
Anticancer Research May 2009, 29 (5) 1575-1578;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Acknowledgements
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • The FSHR Expression in Head and Neck Squamous Cell Cancer. A Pilot Immunohistochemical Study
  • Follicle stimulating hormone is an autocrine regulator of the ovarian cancer metastatic niche through Notch signaling
  • Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target
  • FSH enhances the proliferation of ovarian cancer cells by activating transient receptor potential channel C3
  • Google Scholar

More in this TOC Section

  • Laparotomy After Total Pelvic Exenteration: Current Status and Techniques for Ileal Conduit Preservation
  • Pregabalin for Opioid-resistant Neuropathic Pain in Bone Metastases
  • Life-threatening Pneumonitis Induced by Osimertinib Monotherapy as a First-line Treatment for Epidermal Growth Factor Receptor Mutation-positive Non-small-cell Lung Cancer: A Retrospective Case-series Study
Show more Clinical Studies
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire